VPIM
BPMC

Vanguard Personalized Indexing Management’s Blueprint Medicines BPMC Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,055
Closed -$648K – 1999
2025
Q2 		$648K Buy
5,055
+1,262
+33% +$131K 0.01% 1077
2025
Q1 		$336K Sell
3,793
-14
-0.4% -$1.37K 0.01% 1295
2024
Q4 		$332K Sell
3,807
-786
-17% -$72K 0.01% 1293
2024
Q3 		$425K Buy
4,593
+317
+7% +$31.5K 0.01% 1180
2024
Q2 		$461K Buy
4,276
+485
+13% +$48.5K 0.01% 1076
2024
Q1 		$360K Buy
3,791
+315
+9% +$27K 0.01% 1187
2023
Q4 		$321K Buy
+3,476
New +$225K 0.01% 1193
2023
Q3 		– Sell
-3,313
Closed -$209K – 1494
2023
Q2 		$209K Buy
+3,313
New +$180K 0.01% 1315

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Vanguard Personalized Indexing Management's BPMC Position: Q3 2025 in Review

Vanguard Personalized Indexing Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 5,055 shares — an estimated $648K sold.

Vanguard Personalized Indexing Management first reported a position in BPMC in Q2 2023 and held it in 8 quarters. The position peaked at $648K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Vanguard Personalized Indexing Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Vanguard Personalized Indexing Management sold 5,055 Blueprint Medicines shares in Q3 2025, an estimated $648K.
  • Vanguard Personalized Indexing Management first reported a position in Blueprint Medicines in Q2 2023 and held it in 8 quarters.
  • Vanguard Personalized Indexing Management's Blueprint Medicines position peaked at $648K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Vanguard Personalized Indexing Management's 13F filing for Q3 2025, filed 31 Oct 2025.